Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 9/20 | 0.52 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1408413 | 0.84 | NR1I2 (0.42) | NR1I2ALDH1A1LMNAKDM4EMAPT | |
| SCHEMBL29394648 | 0.84 | NR1I2 (0.42) | NR1I2ALDH1A1LMNAKDM4EMAPT | |
| SCHEMBL11326122 | 0.84 | LMNA (0.53) | NR1I2TP53ALDH1A1CYP3A4KMT2A | |
| SCHEMBL3869436 | 0.82 | KDM4E (0.43) | TP53ALDH1A1CYP3A4KMT2AKDM4E | |
| SCHEMBL1011692 | 0.79 | KDM4E (0.44) | TP53ALDH1A1CYP3A4KMT2AKDM4E | |
| SCHEMBL13532209 | 0.79 | MEN1 (0.46) | TP53ALDH1A1CYP3A4KMT2ALMNA | |
| SCHEMBL14688241 | 0.78 | RIPK2 (0.44) | TP53ALDH1A1CYP3A4KMT2ALMNA | |
| Hydrochloric Acid SCHEMBL3190696 | 0.78 | MEN1 (0.48) | TP53ALDH1A1CYP3A4KMT2ALMNA | |
| SCHEMBL13532214 | 0.76 | MEN1 (0.46) | TP53ALDH1A1CYP3A4KMT2ALMNA | |
| SCHEMBL31265705 | 0.75 | LMNA (0.40) | ALDH1A1KMT2ALMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090209451-A1 | HETEROARYLAMINOPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-08-20 | — | — | US | disclosed |
| US-20090209451-A1 | HETEROARYLAMINOPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-08-20 | — | — | US | disclosed |
| US-20090209451-A1 | HETEROARYLAMINOPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-08-20 | — | — | US | disclosed |
| US-7517878-B2 | Heteroarylaminopyrazole derivatives useful for the treatment of diabetes | BAYER PHARAMCEUTICALS CORPORATION (US) | 2009-04-14 | — | — | US | disclosed |
| US-7517878-B2 | Heteroarylaminopyrazole derivatives useful for the treatment of diabetes | BAYER PHARAMCEUTICALS CORPORATION (US) | 2009-04-14 | — | — | US | disclosed |
| US-7517878-B2 | Heteroarylaminopyrazole derivatives useful for the treatment of diabetes | BAYER PHARAMCEUTICALS CORPORATION (US) | 2009-04-14 | — | — | US | disclosed |
| US-20050192294-A1 | Heteroarylaminopyrazole derivatives useful for the treatment of diabetes | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050192294-A1 | Heteroarylaminopyrazole derivatives useful for the treatment of diabetes | GPR119, GOT2, IAPP | NR1I2 380/4885TP53 2635/4885ALDH1A1 943/4885 |
| US-20090209451-A1 | HETEROARYLAMINOPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES | GPR119, GOT2, IAPP | NR1I2 380/4885TP53 2635/4885ALDH1A1 943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.